ROIV
Roivant Sciences Ltd.
A biopharmaceutical company that develops experimental drugs for autoimmune and rare diseases through a family of nimble subsidiaries it calls 'Vants' — including Immunovant, Priovant, and Pulmovant — each focused on a specific drug candidate. Founded in 2014 by entrepreneur Vivek Ramaswamy, the name blends 'ROI' (return on investment) with the '-vant' suffix stamped on every subsidiary. Its most advanced candidate, brepocitinib, is under FDA review for the rare muscle disease dermatomyositis.
CINS: G76279101CUSIP: G76279101HealthcareUS3 holders
Total Value
$322.37M
Total Shares
9.11M
Net Share Change
+829.8K
Activity
2 buying1 selling
Investor
Value
Shares
Weight
Change
